Fazila Seker, PhD, has over 20 years of experience nurturing new technologies through the commercialization process in Canada and the U.S. by building teams, raising growth funds, and bringing people together for impact in healthcare, energy, and specialty materials sectors. She has held leadership roles with the GE Global Research Center in Niskayuna, NY; MaRS Innovation and, most recently, as Founder, President and CEO of MOLLI Surgical in Toronto, Canada (acquired by Stryker).

Across her career, Fazila has developed a diverse portfolio of medical device opportunities with applications ranging from ultrasound to breast cancer. She also co-produced a crowd-funding campaign to promote a new medical device for monitoring breast cancer treatment. That work won national recognition in the Globe and Mail’s Top 10 Canadian crowdfunding list.

Under Fazila’s leadership, MOLLI Surgical established sales and clinical operations in the U.S. and Canada. Within four years, their efforts meant patients at some of the world’s top hospitals—such as Princess Margaret Cancer Centre in Toronto, Canada and The Christ Hospital Health Network in Ohio—were able to benefit from the company’s groundbreaking medical technology.

Building high-performance, award-winning cultures means Fazila’s teams have been recognized for their work across her career. Those accolades include Gold in the prestigious Medical Design Excellence Awards in the ER & OR (tools and supplies category); TIME Best Inventions 2022; Fast Company Next Big Things in Tech 2022; the 2021 list of Best Workplaces^TM Managed by Women; and the 2022 list of Best Workplaces^TM in Health Care.

Akshay Puli, P. Eng., brings over eight years of experience in product development for complex soft-tissue surgical robotics to his role as Chief Product Officer, grounded in a strong track record for clinical development and a deep understanding of the U.S. and Canadian healthcare systems.

Akshay shaped the clinical user experience for Ottava, Johnson and Johnson’s first soft-tissue robotic platform by advocating for product roadmaps to be built around the clinical team. Separately, Puli also supported surgeons in establishing and expanding their robotic surgical practice using Intuitive Surgical's da Vinci system.

In past Medtech roles, Akshay has successfully aligned R&D decisions to clinical user needs and real-world surgical experience, creating more user-centric product development strategies. At Johnson & Johnson, for example, he trained clinical engineering teams to validate user experience as part of the agile software development process. This strategic approach ensured that developed features for the yet to be released Ottava system remained aligned with clinical intent and customer needs.

Akshay holds a Master of Health Science in Clinical Engineering from the University of Toronto and a Bachelor of Engineering in Biomedical and Electrical Engineering from Carleton University. He is currently an MBA candidate at the University of Johns Hopkins.

Abhijit Saxena has over 15 years of experience developing complex, innovative medical device products with deep expertise in medical robotics. His diverse portfolio spans surgical robotic, navigation and planning technologies in neurosurgical and orthopedic applications, as well as robotic and AI-based data analytics platforms in neurorehabilitation. He has a track record of launching and scaling products from technical conceptualization and development to testing and successful regulatory clearance, with a focus on markets in North America, Europe, and Asia Pacific.

Prior to joining Insight Medbotics, Abhijit was director of engineering at Intellijoint Surgical Inc., senior director of R&D at Bionik Inc., and held progressively senior engineering leadership and mechatronics development roles at Synaptive Medical Inc. Throughout his career, he has successfully scaled engineering teams and overseen portfolio development for a range of products that transform raw innovation into product adoption and additional revenue streams.

Abhijit holds a Bachelors of Engineering in Mechanical Engineering from the University of Pune and a Master of Engineering Science (MESc) in Electrical Engineering and Computer Science from Western University.

Dean Mosca has served as Insight Medbotics' Chairman of the Board since 2019. A life-long serial entrepreneur, he was founder and CEO of Proprietary Nutritionals Inc., a nutritional supplement ingredient company specializing in business to business sales and providing clients with pioneering collaborative opportunities for cross-promotion and public education. Dean sold the company in 2017.

Today, as CEO of Cordra Inc., Dean seeks opportunities to invest in, mentor, and offer strategic support to businesses, entrepreneurs, and start-ups developing exciting and disruptive products and technologies.

Dean is involved in various other companies and organizations as an investor or board member. He is a partner in Frontier Utility Locating Services Ltd., he sits on both the board and the investment sub-committee of Natural Products Canada, is a member of the investment selection committee for Nutrition Capital Network, and a key member in the foundation and advancement of Insight Medbotics through his voluntary work on the board of CSii, the Canadian Centre for Surgical Invention & Innovation.

Fazila Seker, PhD, has over 20 years of experience nurturing new technologies through the commercialization process in Canada and the U.S. by building teams, raising growth funds, and bringing people together for impact in healthcare, energy, and specialty materials sectors. She has held leadership roles with the GE Global Research Center in Niskayuna, NY; MaRS Innovation and, most recently, as Founder, President and CEO of MOLLI Surgical in Toronto, Canada (acquired by Stryker).

Across her career, Fazila has developed a diverse portfolio of medical device opportunities with applications ranging from ultrasound to breast cancer. She also co-produced a crowd-funding campaign to promote a new medical device for monitoring breast cancer treatment. That work won national recognition in the Globe and Mail’s Top 10 Canadian crowdfunding list.

Under Fazila’s leadership, MOLLI Surgical established sales and clinical operations in the U.S. and Canada. Within four years, their efforts meant patients at some of the world’s top hospitals—such as Princess Margaret Cancer Centre in Toronto, Canada and The Christ Hospital Health Network in Ohio—were able to benefit from the company’s groundbreaking medical technology.

Building high-performance, award-winning cultures means Fazila’s teams have been recognized for their work across her career. Those accolades include Gold in the prestigious Medical Design Excellence Awards in the ER & OR (tools and supplies category); TIME Best Inventions 2022; Fast Company Next Big Things in Tech 2022; the 2021 list of Best Workplaces^TM Managed by Women; and the 2022 list of Best Workplaces^TM in Health Care.

Holly Johnson is the Vice President of Robotics and Space Operations (RSO) at MDA, Canada’s leading space company that has provided robotic technology and operational support for space missions including Space Shuttle, International Space Station (ISS), and now Gateway in lunar orbit. In this role, Holly has overall responsibility for the RSO business area, which includes strategy, business development, and delivery of on-orbit robotics, sensors, and rover technologies for the global space market.

Prior to her current position, Holly led business transformation initiatives as the Vice President of Operations at MDA, working with the executive leadership team to modernize and harmonize practices and systems in human resources, finance, information technology, marketing, and business operations. During her tenure in the Operations group, Holly played a key role in the sale of MDA in 2019 to a Canadian-based private equity group and in taking MDA through its initial public offering in 2021 (TSX:MDA).

Holly has a Bachelor’s of Applied Science degree in Mechanical Engineering from the University of Toronto, and is a member of Professional Engineers Ontario. In 2023, Holly received the Best Executive award by the Globe and Mail, and in 2019 she received a Top 40 Under 40 recognition (2019), and was presented with the University of Toronto Alumni Network’s Early Career Award. Holly was also recognized for her professional accomplishments in 2016 by receipt of the Northern Lights Aero Foundation Rising Star Award. She is a passionate advocate for STEM education and women in leadership, and is an active industry representative on panels and in community events.

Stephen R. La Neve brings over forty years of worldwide leadership experience in medical devices, imaging, navigation, robotics, and diagnostics to Insight Medbotics.

Previously, Steve was president of Globus Medical’s Trauma and Joint Reconstruction business units. In that role, Steve managed both global commercial and development activities for spine and joint reconstruction surgical robotic systems, respectively.

Prior to his Globus Medical role, Steve was CEO and a director of Bone Biologics Corporation, CEO of Life Science Enterprises, and CEO of ETEX Corporation, leading to Zimmer Holdings, Inc. acquiring the business of ETEX Holdings, Inc.

He also held global divisional president roles at Medtronic Spine and Biologics and Becton Dickinson Preanalytical Systems. Steve has served as a board member for several healthcare companies in the medical device and diagnostic sections.

He holds a B.S. in Health Planning and Administration from the Pennsylvania State University and an MBA from West Chester University. He is a member of Omicron Delta Epsilon, an international honor society recognizing academic excellence and achievements in economics.

Dr. Matsumoto is an Associate Professor at McMaster University and serves as the Program Director of the Advanced Laparoscopy/Robotics and Endourology Fellowship. A global leader in surgical education, he brings deep expertise in advanced laparoscopic and robotic surgery, with a clinical focus on minimally invasive treatments for prostate and kidney cancers as well as complex stone disease.

His research centers on cutting-edge virtual simulation and robotics training, particularly in the context of prostate cancer care. Renowned internationally for his work on surgical training models, robotic simulation, and technical skill assessment, Dr. Matsumoto has authored more than 100 peer-reviewed publications and contributed 12 textbook chapters in his field.

Christopher is the Chief Commercial Officer of LEM Surgical AG, a Swiss company focused on developing and commercializing next generation surgical robotics platforms.

He has over 25 years of successful medical device experience in both large strategic healthcare companies and successful startup companies. A lot of Christopher’s time has been spent specifically with robotic companies seeking high growth by increasing the adoption of technology that challenges the status quo.

Prior to his most recent position, he was CEO of Harmonic Bionics, CEO of Mazor Robotics, Inc. and Chief Commercial Officer of Mazor Robotics Ltd.  During his career, he has held management positions with Medtronic, Johnson & Johnson, and Tampa General Hospital.

Christopher is a West Point graduate with a master’s degree in Business Administration, as well as Healthcare Administration.

Dr. Anvari, co-founder of Insight Medbotics, and thought leader in the field of Image-Guided Automated Robotics (IGAR), brings his unique skillset to the clinical advancement and approvals/clearances of the world’s first Magnetic Resonance Imaging (MRI) guided breast cancer robot.

Dr. Anvari is a tenured Professor at McMaster University. He is the founding Director of the Centre for Minimal Access Surgery (CMAS) and Scientific Director and CEO of the Centre for Surgical Invention and Innovation (CSii), affiliated with McMaster University and St. Joseph’s Healthcare Hamilton, Ontario, Canada. He is also the Editor-in-Chief of the International Journal of Medical Robotics and Computer-Assisted Surgery.

​Dr. Anvari has also been awarded the Government of Ontario Diamond Award for Innovation in Technology, the Government of Canada Gold Medal of Distinction for Telerobotic Surgery, the NASA-International Space Station (ISS) Research and Development Award for Biology and Medicine (2015), and the Order of Ontario (2017).​

Jeffrey C. Bassett is the Ben and Carmela Du Endowed Chair of Urologic Oncology at Hoag Memorial Hospital Presbyterian in Newport Beach, CA. He specializes in minimally invasive robotic surgery, focal therapies, enhanced diagnostics, and molecular imaging.

Dr. Bassett completed his Society of Urologic Oncology fellowship at Vanderbilt University Medical Center in Nashville, Tennessee. His urologic residency training was at the David Geffen School of Medicine at UCLA, where he also obtained his master’s in public health.

Dr. Bassett has received several distinguished honors throughout his career, including the American Cancer Society’s Excellence in Research Award and the American Society of Clinical Oncology’s Conquer Cancer Foundation Merit Award.

Mark Emberton is a Professor of interventional Oncology with the Division of Surgery and Dean of the Faculty of Medical Science at University College London. He is clinically active and holds the position of Honorary Consultant Urologist at University College London Hospitals NHS Trust where he specializes in prostate cancer.

His academic work focused on developing novel diagnostic strategies and new therapies for men with prostate cancer. Dr. Emberton’s research has resulted in the transformation of both the diagnostic and therapeutics pathways, which have been incorporated into international guidelines.

He has published over 500 peer-reviewed papers, holds a large grant portfolio and international honorary professorships, and lectures widely around the world.

Dr. Sprenkle is an Associate Professor of Urology at Yale University where he has dedicated his career to using the latest technologies to improve prostate cancer diagnosis and treatment. 

He was one of the first physicians in the United States to implement the use of the Penumbra’s Artemis Device. Introduced in 2009, this machine allows surgeons to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.

Dr. Sprenkle is also a pioneer in focal therapy, which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This approach avoids many of the side effects—such as erectile dysfunction and urinary incontinence—that may follow the removal of the whole prostate.

He is always seeking ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life.